Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
Toxicologic Pathology
This Article
Right arrow Free Full Text (Free PDF) Free
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Elangbam, C. S.
Right arrow Articles by Wall, H. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Elangbam, C. S.
Right arrow Articles by Wall, H. G.
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Heart Valve Diseases
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Endocardial Myxomatous Change in Harlan Sprague-Dawley Rats (Hsd:S—D) and CD-1 Mice: Its Microscopic Resemblance to Drug-Induced Valvulopathy in Humans

Chandikumar S. Elangbam

Department of Pathology, GlaxoSmithKline Inc, Research Triangle Park, North Carolina, USA, cse63957{at}gsk.com

Karyn A. Colman

Department of Pathology, ClinTrialsBioResearch (CTBR) Ltd, Quebec, Canada

Ruth M. Lightfoot

Department of Safety Assessment, GlaxoSmithKline Inc, Research Triangle Park, North Carolina, USA

Ronald D. Tyler

Department of Safety Assessment, GlaxoSmithKline Inc, Research Triangle Park, North Carolina, USA

Henry G. Wall

Department of Pathology, GlaxoSmithKline Inc, Research Triangle Park, North Carolina, USA

A full assessment of all heart valves in rats and mice is often impractical and is usually not performed in routine toxicity studies, largely due to an inevitable inconsistency of histological sampling. The majority of reported heart valve changes involve the examination of a single, semirandom section through the heart and the valvulopathy occurring with age or induced by xenobiotics may have been generally underestimated in mice and rats. Here we describe the incidence and microscopic features of endocardial myxomatous change (EMC) in Hsd:S—D rats and CD-1 mice. EMC was common and widespread in both CD-1 mice and Hsd:S—D rats (188 of 220 rats and 96 of 215 mice were affected by EMC). Microscopically, EMC consisted of focal or segmental thickening of valves, primarily due to the presence of fibromyxoid tissue in the subendocardium. Occasionally, fibrin or thrombi deposits and collection of neutrophils or mononuclear cells were observed. These microscopic features were similar to those seen in valvular disease in humans induced by fenfluramine-phentermine (fen-phen), ergot alkaloids (ergotamine, methysergide), and carcinoid syndrome. The mitral valve in rats and pulmonary valve in mice were most frequently affected. An association between murine progressive cardiomyopathy (MPC) and EMC was noted only in rats, suggesting that there may be a possible relationship between MPC and EMC. However, additional research is needed to confirm a relationship between EMC and MPC in rats and/or mice.

Key Words: Endocardial myxomatous change • age-related • Sprague-Dawley rats • CD-1 mice • valvular disease • atrial thrombosis • murine progressive cardiomyopathy.

Toxicologic Pathology, Vol. 30, No. 4, 483-491 (2002)
DOI: 10.1080/01926230290105703
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
S. Droogmans, B. Roosens, B. Cosyns, C. Degaillier, S. Hernot, C. Weytjens, C. Garbar, V. Caveliers, M. Pipeleers-Marichal, P. R. Franken, et al.
Cyproheptadine prevents pergolide-induced valvulopathy in rats: an echocardiographic and histopathological study
Am J Physiol Heart Circ Physiol, June 1, 2009; 296(6): H1940 - H1948.
[Abstract] [Full Text] [PDF]

Home page
 Vet PatholHome page
C. S. Elangbam
REVIEW PAPER: Current Strategies in the Development of Anti-obesity Drugs and Their Safety Concerns
Vet. Pathol., January 1, 2009; 46(1): 10 - 24.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol PatholHome page
K. B. Donnelly
Cardiac Valvular Pathology: Comparative Pathology and Animal Models of Acquired Cardiac Valvular Diseases
Toxicol Pathol, February 1, 2008; 36(2): 204 - 217.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol PatholHome page
K. Yoshizawa, G. E. Kissling, J. A. Johnson, N. P. Clayton, N. D. Flagler, and A. Nyska
Chemical-Induced Atrial Thrombosis in NTP Rodent Studies
Toxicol Pathol, August 1, 2005; 33(5): 517 - 532.
[Abstract] [Full Text] [PDF]